Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy.
about
3-Pyridyl substituted aliphatic cycles as CYP11B2 inhibitors: aromaticity abolishment of the core significantly increased selectivity over CYP1A2The involvement of aldosterone in cyclic stretch-mediated activation of NADPH oxidase in vascular smooth muscle cellsThe pathophysiology of aldosterone in the cardiovascular system.Significance of AT1 receptor independent activation of mineralocorticoid receptor in murine diabetic cardiomyopathy.RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease.The clinical implications of aldosterone escape in congestive heart failure.Adverse cardiorenal effects of aldosterone: is aldosterone antagonism beneficial?Protective effects of angiotensin II interruption: evidence for antiinflammatory actions.Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?Role of mitogen-activated protein kinase pathways in multifactorial adverse cardiac remodeling associated with metabolic syndromeAldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failure.Drug insight: aldosterone-receptor antagonists in heart failure--the journey continues.The incidence and implications of aldosterone breakthrough.Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study).Impact of aldosterone receptor blockade compared with thiazide therapy on sympathetic nervous system function in geriatric hypertensionDeterminants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathyRelations of biomarkers representing distinct biological pathways to left ventricular geometryAldosterone and progression of kidney disease.Sodium and Its Role in Cardiovascular Disease - The Debate Continues.Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work?Aldosterone antagonists in heart failure.Expanding role of mineralocorticoid receptor antagonists in the treatment of heart failure.Mineralocorticoid receptor antagonists: their use and differentiation in Japan.Aldosterone synthase inhibition in hypertension.Aldosterone and the heart: still an unresolved issue?The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy.Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease.Aldosterone and aldosterone antagonists in cardiac disease: what is known, what is new.Effect of spironolactone combined with angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers on chronic glomerular disease.Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension.Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease.Effect of aldosterone breakthrough on albuminuria during treatment with a direct renin inhibitor and combined effect with a mineralocorticoid receptor antagonist.Adding low-dose spironolactone to multidrug regimens for resistant hypertension.Association of -344/T/C aldosterone synthase polymorphism (CYP11B2) with left ventricular structure and humoral parameters in young normotensive men.Long-term effect of efonidipine therapy on plasma aldosterone and left ventricular mass index in patients with essential hypertension.Long-term antiproteinuric effect of dual renin-angiotensin system blockade.The effects of spironolactone on nephron function in patients with diabetic nephropathy.Role of aldosterone in diabetic nephropathy.Aldosterone breakthrough does not alter central hemodynamics.
P2860
Q28484774-4C4F9282-BA3D-435C-AE6D-FBFF8BF4F86DQ28578712-725FB082-B214-4BF5-BE47-160DA08ECBD5Q34967661-DB18FF75-6085-4749-B6D4-0A06036891E7Q35130314-7E4AC693-C025-43C1-AAF9-0F41343054ACQ35209084-A2961AA4-1A2E-4D9E-9E36-D5F18D0A3EA2Q35859269-79C68762-7B7F-4F9C-B626-18CDE74F9C3DQ36124918-F33E4D9D-5A23-4169-88D6-2DAFB9E4B7BAQ36257966-9BD0FC7A-44C9-4C6F-A96F-8FADDF58F03FQ36437145-3446A1BF-F834-48B3-846F-DBBDD134286DQ36567326-7DA21047-B413-483D-A6DF-C6F79209BF6CQ36643672-C0FE86C0-ADD4-454F-953E-55448A1521B5Q36858827-20C48DAE-0EB3-46E6-AA68-D2C84250776BQ36918649-278EF5BB-4F39-4047-9FE6-676AC17EAF60Q37010254-3D0C9C7E-483E-46B1-963B-4403C969E95AQ37186757-100164D5-850B-46A5-9997-9DCB4C521B15Q37212380-42E96AFC-7462-452E-AC5D-98BC3CD34BBFQ37355268-5F2AB76F-2603-46AF-BEC1-D1037CAA445CQ37378291-81BF4521-0BF1-40EA-BD56-797F0D35A9EFQ37528633-32F2A6BB-CDBE-4ACC-BF20-0E0B8960BABDQ37574913-1C4D5F68-630B-410E-A4A4-5FAF5BFF2116Q37709432-EA1AA105-F193-4823-BEBE-01D0AE84C18AQ37821172-769856DB-6128-4A8B-ACCD-C3C013D0B4BFQ38040730-1D68B3EF-F408-4ACA-A8B8-FF4F37734808Q38061551-BE154536-5DA6-4D4D-8E3B-CC9812F7AC2CQ38126805-E8A2A2FC-4DB0-4EBB-ABE6-AAA786B7DD84Q38263511-7C9C5EEA-BF17-46D7-A6CC-0384A66040B3Q38374536-FD894CFD-9E26-468B-8279-CC4B421C44F1Q38533385-FA86787A-6297-4519-A363-E6BC67CB8898Q40362633-D36F3EA8-243F-4C72-B4D4-0454588C01A5Q41773994-6EA8DBC4-0883-4F0D-BCEA-33966C2089EAQ43238313-EC8B21B4-13A2-4F8D-A676-2C3ABF164CE4Q43238726-459A4737-2497-47FF-A35A-9FFAFF55F23AQ43451334-B6694384-1F26-4306-8577-9E26DFBA8655Q44884859-5C1EE897-E854-4AD6-B36E-EBDB6E7C12C0Q44956538-D2696449-1CA8-4ED5-9717-B3BCEF92FD87Q45981857-C5347F89-C9BF-4AE9-ACEF-C3F9B695B6E3Q46020132-AAA67642-0AAE-45BD-9162-6E10170B4894Q46240721-6351674B-2A08-46DC-8292-72F01052B8B7Q46713051-AB63D387-C13E-463F-ADC7-4188A7D3F5A2Q49383817-E4E0EA1B-C9DF-4109-8652-545C7DA9F22C
P2860
Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Aldosterone escape during angi ...... left ventricular hypertrophy.
@en
Aldosterone escape during angi ...... left ventricular hypertrophy.
@nl
type
label
Aldosterone escape during angi ...... left ventricular hypertrophy.
@en
Aldosterone escape during angi ...... left ventricular hypertrophy.
@nl
prefLabel
Aldosterone escape during angi ...... left ventricular hypertrophy.
@en
Aldosterone escape during angi ...... left ventricular hypertrophy.
@nl
P2860
P1476
Aldosterone escape during angi ...... left ventricular hypertrophy.
@en
P2860
P356
10.1177/147323000102900103
P577
2001-01-01T00:00:00Z